share_log

リボミック:軟骨無形成症治療薬(umedaptanib pegol)前期第II相臨床試験低用量群で顕著な効果(成長速度増加)確認のお知らせ

Ribomic: Notice of confirmation of remarkable effects (increase in growth rate) in the low dose group in early phase II clinical trials for achondroplasia (umedaptanib pegol)

JPX ·  Nov 5 14:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more